L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 15:23:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      14 TO ITERATE

100.0% PROCESSED       14 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:            56 TO       504
PROJECTED ANSWERS:                3 TO       163

L2             3 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 15:23:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     300 TO ITERATE

100.0% PROCESSED      300 ITERATIONS                              20 ANSWERS
SEARCH TIME: 00.00.01

L3            20 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   148.15     148.36

FILE 'CAPLUS' ENTERED AT 15:23:44 ON 09 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 May 2003 VOL 138 ISS 20
FILE LAST UPDATED: 8 May 2003 (20030508/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:137218 CAPLUS
DOCUMENT NUMBER: 134:193607
TITLE: Preparation of phenanthrolin-7-one derivatives and their therapeutic uses as antitumoral medicines
INVENTOR(S): Delfourne, Evelyne; Darro, Francis; Bastide, Jean; Kiss, Robert; Frydman, Armand
PATENT ASSIGNEE(S): Laboratoire L. Lafon, Fr.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012632	A2	20010222	WO 2000-FR2313	20000811
WO 2001012632	A3	20010719		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2797446	A1	20010216	FR 1999-10493	19990813
FR 2797446	B1	20011102		
BR 2000013239	A	20020423	BR 2000-13239	20000811
EP 1202993	A2	20020508	EP 2000-958679	20000811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NO 2002000669	A	20020415	NO 2002-669	20020211

PRIORITY APPLN. INFO.: FR 1999-10493 A 19990813
WO 2000-FR2313 W 20000811

OTHER SOURCE(S): CASREACT 134:193607; MARPAT 134:193607

GI



I



II

AB The invention concerns a pharmaceutical compn. comprising an efficient amt. of a compd. selected among the compds. I [R1, R2, R3, R4, R5 = H, halogen, C1-6-alkyl, OH, CHO, OR8, CO2H, CN, CO2R8, CONHR8, CONR8R9, NH2, NHR8, N(R8)2, NHCH2CH2NMe2, NHCH2CH2Cl, NHCOR8, morpholino, NO2, SO3H, CH2N(CO2R8)CH2CO2R9, CH2N(CO2R8)CH2Ar; R6 = H, halogen, C1-6-alkyl, (CH2)nR10, ; R7 = H, C1-6-alkyl, Ph-C1-4-alkyl, NR15R16; R8, R9 = C1-6-alkyl, Ph-C1-4-alkyl; R10 = halogen, OH, C1-6-alkoxy, OC(:O)-C1-6-alkyl, CN, CO2Et, COR11; R11 = Ph-C1-4-alkyl, NR12R13; R12 , R13 = H, C1-6-alkyl, Ph-C1-4-alkyl, (CH2)nR14; R14 = halogen, C1-6-alkoxy, NMe2; R15, R16 = H, C1-6-alkyl, Ph-C1-4-alkyl, (CH2)nR17; R17 = H, halogen, OH, C1-6-alkoxy; Ar = C6-14-aryl; n = 1 - 6] and II or their pharmaceutically acceptable salts. Thus, I [R1 = R2 = R3 = R4 = R5 = R6 = R7 = H (CRL8293)] and II [R1 = R2 = R3 = R4 = R5 = R6 = R7 = H (CRL8294)] were prepd. from quinoline-5,8-dione via Diels-Alder with crotonaldehyde dimethylhydrazone followed by cyclocondensation of the resulting quinone III with Me2NCMe(OEt)2. I (R1 = R2 = R3 = R4 = R5 = R6 = R7 = H) and II (R1 = R2 = R3 = R4 = R5 = R6 = R7 = H) have interesting cytotoxic properties [DMT = 10 mg/Kg (DMT = max. tolerable dose); -33% and -36%, resp. tumor surface diminution {murin mammary carcinoma (MXT-HI)}; -45% and -64% , resp. tumor surface diminution [{murin mammary adenocarcinoma (MXT-HS)}]; and, for II, T/C = 136% (lymphoma L1210)] leading to a therapeutic use as antitumoral medicines.

IT **266306-76-7P**, CRL 8294 **327184-13-4P**, CRL 8364 **327184-14-5P** **327184-15-6P**, CRL 8401 **327184-16-7P** , CRL 8440 **327184-17-8P**, CRL 8479 **327184-18-9P** **327184-19-0P**, CRL 8485 **327184-20-3P** **327184-21-4P** , 3-(Acetoxymethyl)-9-methoxy-7H-pyrido[4,3,2-de][1,10]phenanthrolin-7-one **327184-22-5P**, CRL 8830 **327184-33-8P**, CRL 8367 **327184-35-0P**, CRL 8388 **327184-37-2P**, CRL 8441 **327184-39-4P**, CRL 8482 **327184-41-8P**, CRL 8483 **327184-43-0P**, CRL 8486 **327184-45-2P**, CRL 8487 **327184-47-4P**, CRL 8480 **327184-49-6P**, CRL 8481
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenanthrolin-7-one derivs. and their therapeutic uses as antitumoral medicines)

RN 266306-76-7 CAPLUS

CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one (9CI) (CA INDEX NAME)



RN 327184-13-4 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 11-methoxy- (9CI) (CA INDEX NAME)



RN 327184-14-5 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 11-chloro- (9CI) (CA INDEX NAME)



RN 327184-15-6 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 4-methoxy- (9CI) (CA INDEX NAME)



RN 327184-16-7 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 4,11-dimethoxy- (9CI) (CA INDEX NAME)



RN 327184-17-8 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 4,9-dimethoxy- (9CI) (CA INDEX NAME)



RN 327184-18-9 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 9-methoxy- (9CI) (CA INDEX NAME)



RN 327184-19-0 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 9,11-dimethoxy- (9CI) (CA INDEX NAME)



RN 327184-20-3 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 3-[(acetyloxy)methyl]- (9CI)

(CA INDEX NAME)



RN 327184-21-4 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 3-[(acetyloxy)methyl]-9-methoxy- (9CI) (CA INDEX NAME)



RN 327184-22-5 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 2-(2-chloroethyl)- (9CI) (CA INDEX NAME)



RN 327184-33-8 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 11-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 327184-35-0 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 11-hydroxy- (9CI) (CA INDEX NAME)



RN 327184-37-2 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 11-(dimethylamino)-4-methoxy- (9CI) (CA INDEX NAME)



RN 327184-39-4 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthroline-10-carboxylic acid, 7-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 327184-41-8 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthroline-7,9(8H)-dione (9CI) (CA INDEX NAME)



RN 327184-43-0 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 9-chloro-11-(dimethylamino)-(9CI) (CA INDEX NAME)



RN 327184-45-2 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 4-hydroxy-, dihydriodide (9CI) (CA INDEX NAME)



●2 HI

RN 327184-47-4 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 4-chloro- (9CI) (CA INDEX NAME)



RN 327184-49-6 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 4-(dimethylamino)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:177139 CAPLUS
DOCUMENT NUMBER: 132:303121
TITLE: Mechanism of action studies of cytotoxic marine alkaloids: ascididemin exhibits thiol-dependent oxidative DNA cleavage
AUTHOR(S): Matsumoto, Sandra S.; Sidford, Mathew H.; Holden, Joseph A.; Barrows, Louis R.; Copp, Brent R.
CORPORATE SOURCE: Departments of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, 84112, USA
SOURCE: Tetrahedron Letters (2000), 41(10), 1667-1670
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The cytotoxic marine alkaloid ascididemin has been shown to be a thiol-dependent DNA cleaving agent. Previous mechanisms of action studies have concluded that DNA and/or the DNA processing enzyme topoisomerase II were the cellular targets for the alkaloid - this is the first direct evidence that a pyridoacridone alkaloid can cause DNA cleavage under physiol. conditions.
IT **266306-76-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(cytotoxic ascididemin exhibits thiol-dependent oxidative DNA cleavage)
RN 266306-76-7 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.49	157.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.30	-1.30

STN INTERNATIONAL LOGOFF AT 15:24:03 ON 09 MAY 2003